Eli Lilly's retatrutide - a first-in-class triple GLP-1/GIP/glucagon receptor agonist - delivered bariatric-surgery-level weight loss across its phase 3 TRIUMPH program in obesity and type 2 diabetes, with the 12 mg dose achieving roughly 28.7% mean weight reduction at 68 weeks and about 30.3% (~85 lb) in a pre-specified 104-week extension with no plateau. In TRANSCEND-T2D-1, retatrutide cut HbA1c by 1.7-2.0 percentage points at 40 weeks, and up to 68% of participants hit the composite of A1c <=6.5% plus >=10% weight loss. The data position retatrutide at the top of the obesity efficacy ladder, ahead of tirzepatide and semaglutide, pending regulatory filings.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.